NSFDC showcases success in bolstering entrepreneurship amongst depressed classes (See 'Corp Brief') Govt reviews BSNL performance for Q1 FY 2026-27 (See 'Corp Brief') India enters next phase of governance transformation with AI-driven administrative reforms: MoS (See 'Corp Brief') IPR - If infringing use is coupled alleged fraudulent online payment & earning schemes, conduct may be treated not merely as trademark infringement and passing off, but also as phishing & cyber fraud justifying urgent intervention: HC (See 'Legal Desk') MeitY releases 2nd edition of the Digital Threat Report 2025-26 for BFSI Sector (See 'Corp Brief') On Eve of Bharat Tex 2026, India prepares to host World's Largest Global Textiles Expo (See 'Corp Brief') IPR - In vitro screening method functions as diagnostic process, which is barred from patentability u/s 3(i) of Patents Act: HC (See 'Legal Desk') 'SANKALP' to guide CPWD's Journey towards Future-Ready Organisation: Union Minister (See 'Corp Brief') Healthcare facilities worth Rs 668 Crore to benefit 53 Lakh ESI Beneficiaries (See 'Corp Brief') Chouhan gives message of Green India during dialogue with Vriksh Mitra (See 'Corp Brief') IPR - If on visual comparison, rival medicinal marks are strikingly similar in essential features, overall get up and packaging, and where trade channels and consumer base are common, likelihood of deception is sufficient to justify interim injunction: HC (See 'Legal Desk') Lakhanpur among first towns selected under PM SVANidhi 'Street Food Hub' Plan: MoS (See 'Corp Brief') Paswan hails PMFME Scheme's landmark achievement of 2 lakh Credit-Linked Beneficiaries (See 'Corp Brief') 500 officials participate in inaugural webinar on Anemia and Adolescent Health (See 'Corp Brief') IPR - Purpose of summary judgment in commercial suits is to ensure time-bound disposal and that trial is not default norm: HC (See 'Legal Desk') Ministry of Textiles to organise 'Weave The Future 4.0 - Upcycling Edition' at Dilli Haat (See 'Corp Brief') IPR - For purposes of Sec 57 of Trade Marks Act, foreign proprietor may succeed in rectification by proving that its mark had acquired actionable recognition, even without formal commercial launch or direct sales: HC (See 'Legal Desk') Nadda chairs Steering Group Meeting of Ayushman Bharat Digital Mission (See 'Corp Brief') DoP and TRAI to conduct Village-Level Telecom Network Performance Survey (See 'Corp Brief') IBC - Demand notice in Form B under Rule 7(1) of Personal Guarantor Rules is only procedural requirement prior to filing and does not amount to invocation of guarantee: NCLT (See 'Legal Desk') Tech Innovation and disruption in Construction Industry (See 'CORP EINSICHT')

Print

NPPA monitors prices of scheduled & non-scheduled medicines

Published: Jul 30, 2024

By TIOLCorplaws News Service

NEW DELHI, JULY 30, 2024: AS per the provisions of Drugs (Prices Control) Order, 2013 (DPCO, 2013), formulations listed in Schedule-I of the DPCO are defined as scheduled formulation under section 2(1)(zb) of DPCO, 2013. Formulations not included in Schedule-I are defined under Para 2(1)(v) of DPCO, 2013 as non-scheduled formulation. Thus, both schedule and non-schedule drugs are covered under DPCO, 2013. 

As per the extant provisions of DPCO, 2013, the ceiling prices of scheduled medicines are revised annually on the basis of Wholesale Price Index (WPI) (all commodities) for preceding calendar year by National Pharmaceutical Pricing Authority (NPPA), on or before 1st April of every year and is notified by the Government on the 1st day of April every year. The details of price fixed by NPPA are available at NPPA's website i.e. nppaindia.nic.in.  In case of non-scheduled formulation (branded or generic), as per para 20 of DPCO, 2013, no manufacturers can increase Maximum Retail Price (MRP) by more than 10% of MRP during preceding 12 months.  The maximum permissible increase in prices, as per the provisions of DPCO, 2013 for scheduled and non-scheduled drugs may or may not be availed by their respective manufacturers based on commercial considerations and market dynamics.

Under the Drugs and Cosmetics Act, 1945 and Rules thereunder, manufacturers of drugs are required to comply with conditions of manufacturing licence and the requirements of Good Manufacturing Practices (GMP).  As per the Drugs Rules, 1945, the manufacturing, testing, labeling, packaging, storage and distribution are required to be carried out in compliance with the conditions of license including the Good manufacturing practices (GMP) prescribed under the Schedule M of the Drugs Rules, 1945. In case of violation, the Licensing Authority is empowered to take action as per the said Act and Rules.

NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013.  Action is taken against companies, found selling formulations at prices higher than the permissible price, and the overcharged amount is recovered from the company as per the relevant provisions of the DPCO, 2013. During the financial year 2023-24, Rs. 72.73 crore was recovered from the defaulting companies.

This information was given by the Union Minister of State for Chemicals and Fertilizers Anupriya Patel in Rajya Sabha in reply to a question today.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.